the absolute excess risk of stroke in patients older than age 75 years receiving thrombolytic treatment was <1%, and there was no age-associated excess in the risk of other major bleeding ...

It has now been 25 years since prourokinase was in the spotlight as a potential treatment for acute ischaemic stroke. In 1999, the PROACT-II randomised controlled trial compared intra-arterial ...

In the early 1990s, a pivotal randomised trial sponsored by the National Institute of Neurological Disorders and Stroke ...

In total, two hundred and thirty-five patients were diagnosed with ischemic stroke, of which eighty-two patients received thrombolytic treatment. Ultimately, eighty-eight interviews were conducted ...

Fast response is vital Although advances have been made in the treatment of stroke including thrombolytic drugs such as Alteplase they have a modest window of utilisation and are known to cause ...

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic stroke. T ...

While advances such as intravenous thrombolytic agents—TNKase ... Prolong Pharmaceuticals is developing PP-007 as a treatment for acute ischemic stroke to lessen the debilitating comorbidities ...